# Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

> **NCT02836873** · PHASE3 · COMPLETED · sponsor: **Theracos** · enrollment: 312 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Bexagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02836873
- **Lead sponsor:** Theracos
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-23
- **Primary completion:** 2018-01-11
- **Final completion:** 2018-01-11
- **Target enrollment:** 312 (ACTUAL)
- **Last updated:** 2021-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02836873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02836873, "Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02836873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*